Ventyx’s RX for Going Public

Third Point, Citadel, and other hedge funds are gearing up for this biopharma IPO less than a month after investing in the company’s latest financing round.

Stephen Taub September 30, 2021

Michael Nagle/Bloomberg

Now this is what you call late-stage financing. Ventyx Biosciences Wednesday evening filed initial plans to go public, just 20 days after it closed on its latest private financing round. At least five hedge fund firms have an interest in the company, two of whom hold sizable

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login